Back to search results

A Study of IMG-007 for Moderate-to-Severe Atopic Dermatitis

This study is testing a new treatment called IMG-007 for adults with moderate-to-severe atopic dermatitis (eczema). Researchers want to see how well IMG-007 works and if it's safe compared to a placebo (an inactive substance). You might be able to join if you are between 18 and 74 years old and have moderate-to-severe atopic dermatitis that hasn't responded well to topical treatments. The main goal is to see how much your eczema improves after 24 weeks of treatment. The study plans to enroll 405 participants, but its current recruitment status is unclear.

Study design
This is a Phase 2b, randomized, double-blind study, meaning participants will be randomly assigned to receive either IMG-007 or a placebo, and neither you nor your doctor will know which you are receiving. The study will include about 405 adult participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main treatment period is up to 48 weeks, with the primary outcome measured at Week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07037901

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Recruiting
PHASE2Ages 18–74InterventionalTreatment
Inmagene LLC
~405 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:IMG-007Placebo

At a glance

Recruiting sites
23 of 30 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean percent change from baseline in EASI at Week 24
Measured over Baseline, Week 24

Conditions

Atopic Dermatitis
Atopic Dermatitis Eczema
Eczema

Explore related trials

Atopic Dermatitis

Where it's being run

30 sites across 21 states
New York3
Ontario3
California2
Florida2
Ohio2
Victoria2
British Columbia2
Illinois1

Who to contact

ADAPTIVE Study Lead
[email protected]
(858) 345-6927
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Moderate-to-severe AD
Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable
Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of childbearing potential or of childbearing potential and agrees to use a highly effective method of contraception
Male participants must agree to use a highly effective method of contraception
EASI score ≥16
vIGA-AD score ≥3
≥10% body surface area (BSA) of AD involvement
Mean peak pruritus numerical rating scale ≥ 4 during 7-days before randomization

Exclusion

Positive hepatitis B, hepatitis C, or human immunodeficiency virus infection
Evidence of active or latent tuberculosis (TB)
History of untreated or inadequately treated TB infection
Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals
Active unstable pruritic skin conditions in addition to AD that would interfere with the assessment of AD based on the investigator's clinical judgement
Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study
Having received any of the specified therapies within the specified timeframe(s) prior to the Baseline visit

What this trial measures

  • Mean percent change from baseline in EASI at Week 24Baseline, Week 24